International Journal of Cancer · 2000 · 54 citations · 17 references
MedicineOncologyPharmacologyMolecular OncologyOncogenesSignal TransductionOncogene ActivationOncogenic Signaling PathwaysReceptor Tyrosine Kinase OncogenesReceptor Tyrosine Kinase SignalingThyroid CancerTyrosine Kinase InhibitorsAdaptor Protein SignalingProtein Tyrosine PhosphorylationReceptor Tyrosine Kinase ActivationRet InhibitorsSelective Tyrosine Kinase InhibitorsSignal Transduction Pathway ActivationTherapeutic Tyrosine Kinase InhibitorsTyrosine Phosphorylation Signaling
ret-derived oncogenes are frequently and specifically expressed in thyroid tumors. In contrast to the ret receptor, ret oncoproteins are characterized by ligand-independent tyrosine-kinase activity and tyrosine phosphorylation. In this study, novel synthetic arylidene 2-indolinone compounds were evaluated as inhibitors of the ret/ptc1 tyrosine kinase. Four compounds inhibited ret/ptc1 activity in immunokinase assay (IC50 27-42 microM) including one (1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl) methylene)-2H-indol-2-one) (Cpd 1) that selectively inhibited the anchorage-independent growth of NIH3T3 transformants expressing the ret/ptc1 gene (NIH3T3ptc1 cells). Following exposure to Cpd 1, the transformed phenotype of NIH3T3ptc1 cells was reverted, within 24 hr, to a normal fibroblast-like morphology in adherent-cell culture. In these cells, the constitutive tyrosine phosphorylation of ret/ptc1, of the transducing adaptor protein shc and of a series of co-immunoprecipitated peptides became much reduced, as demonstrated by immunoprecipitation/Western-blot analyses. Data presented provide additional evidence that ret/ptc1 is directly implicated in malignant transformation, and demonstrate the ability of Cpd 1 to interfere in the signal transduction pathway constitutively activated by the ret/ptc1 oncoprotein. These results confirm the interest of the arylidene 2-indolinone class of tyrosine-kinase inhibitors as tools for the study of ret signaling and the control of cell proliferation in ret- and ret/ptcs-associated diseases.
17
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
Eve J. Lowenstein, Roger J. Daly, Andreas Batzer et al. · Cell · 1992 · 1.7K citations · Full text
T. Annie T. Fong, Laura K. Shawver, Li Sun et al. · PubMed · 1999 · 1K citations
Medicine, Oncology, Pharmacology +16